Search

Search Constraints

You searched for: Author/Creator Hall, David B

Search Results

1. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Issue 10080 (29th April 2017)

2. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. (October 2018)

3. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Issue 9 (26th June 2018)